Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com..
Gastroesophageal adenocarcinoma (GEA) represents a very heterogeneous disease and patients in advanced stages have a very poor prognosis. Although several molecular classifications have been proposed, precision medicine for HER2-amplified GEA patients still represents a challenge. Despite improvement in clinical outcomes obtained by adding trastuzumab to first-line platinum-based chemotherapy, no other anti-HER2 agents used first-line or beyond progression have demonstrated any benefit. Several factors contribute to this failure. Among them, variable HER2 amplification assessment, tumour heterogeneity, molecular mechanisms of resistance and microenvironmental factors could limit the effectiveness of anti-HER2 blockade. Identifying the factors responsible for both primary and acquired resistance is a priority for providing an improved, personalised approach. In this review, we examine current treatments for HER2-amplified GEA, their potential mechanisms of resistance and the ways to overcome them, investigating the most relevant translational studies with anti-HER2 agents in GEA, as well as novel agents under development in this field.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Annals of oncology : official journal of the European Society for Medical Oncology - 30(2019), 8 vom: 01. Aug., Seite 1254-1264 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gambardella, V [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.06.2020 Date Revised 09.06.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/annonc/mdz143 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM296657298 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM296657298 | ||
| 003 | DE-627 | ||
| 005 | 20231225090318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdz143 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0988.xml |
| 035 | |a (DE-627)NLM296657298 | ||
| 035 | |a (NLM)31046106 | ||
| 035 | |a (PII)S0923-7534(19)31274-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gambardella, V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.06.2020 | ||
| 500 | |a Date Revised 09.06.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a Gastroesophageal adenocarcinoma (GEA) represents a very heterogeneous disease and patients in advanced stages have a very poor prognosis. Although several molecular classifications have been proposed, precision medicine for HER2-amplified GEA patients still represents a challenge. Despite improvement in clinical outcomes obtained by adding trastuzumab to first-line platinum-based chemotherapy, no other anti-HER2 agents used first-line or beyond progression have demonstrated any benefit. Several factors contribute to this failure. Among them, variable HER2 amplification assessment, tumour heterogeneity, molecular mechanisms of resistance and microenvironmental factors could limit the effectiveness of anti-HER2 blockade. Identifying the factors responsible for both primary and acquired resistance is a priority for providing an improved, personalised approach. In this review, we examine current treatments for HER2-amplified GEA, their potential mechanisms of resistance and the ways to overcome them, investigating the most relevant translational studies with anti-HER2 agents in GEA, as well as novel agents under development in this field | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HER2 amplification | |
| 650 | 4 | |a drug resistance | |
| 650 | 4 | |a gastroesophageal cancer | |
| 650 | 4 | |a new anti-HER2 drugs | |
| 650 | 4 | |a tumour heterogeneity | |
| 650 | 4 | |a tumour microenvironment | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a ERBB2 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Fleitas, T |e verfasserin |4 aut | |
| 700 | 1 | |a Tarazona, N |e verfasserin |4 aut | |
| 700 | 1 | |a Cejalvo, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Gimeno-Valiente, F |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Ciarpaglini, C |e verfasserin |4 aut | |
| 700 | 1 | |a Huerta, M |e verfasserin |4 aut | |
| 700 | 1 | |a Roselló, S |e verfasserin |4 aut | |
| 700 | 1 | |a Castillo, J |e verfasserin |4 aut | |
| 700 | 1 | |a Roda, D |e verfasserin |4 aut | |
| 700 | 1 | |a Cervantes, A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology : official journal of the European Society for Medical Oncology |d 1990 |g 30(2019), 8 vom: 01. Aug., Seite 1254-1264 |w (DE-627)NLM012606308 |x 1569-8041 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2019 |g number:8 |g day:01 |g month:08 |g pages:1254-1264 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/annonc/mdz143 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2019 |e 8 |b 01 |c 08 |h 1254-1264 | ||